[In Focus] Research digest: pioneering an oral GLP-1 receptor agonist

The ability to achieve and maintain optimal metabolic control in type 2 diabetes relies on a combination of lifestyle changes, education, access to disease management tools, and pharmacological treatment. Patients achieving near-normal HbA1c see a decreased risk of diabetes-related complications. For many years, efforts have been directed at developing new pharmacological agents beyond the traditional mainline diabetes treatments (insulin, metformin, and sulfonylureas), especially for patients unresponsive to existing interventions.

Bekijk het originele bericht